Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice.

ABSTRACT: The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the gap between research and clinical care. Although implementation feasibility may vary across regions and settings, improving the availability and accuracy of biomarkers, especially plasma biomarkers, is expected to enhance the applicability of these criteria in clinical practice. The Fall 2023 Alzheimer's Association Research Roundtable (AARR) meeting served as a forum for gathering industry perspectives and feedback on these revised criteria, ensuring that the new criteria inform research, clinical trial design, and

SUBMITTER: Jack CR 

PROVIDER: S-EPMC11694534 | biostudies-literature | 2024 Oct-Dec

REPOSITORIES: biostudies-literature